Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 14/20 | 0.70 |
| ▸ | CHRNA4 | P43681 | 14/20 | 0.70 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.70 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.70 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.70 |
| ▸ | AKT1 | P31749 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3358522 | 0.93 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL13335284 | 0.92 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL3357008 | 0.91 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL3360278 | 0.91 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL3359029 | 0.91 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL3361026 | 0.91 | CHRNB2 (0.63) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL3361073 | 0.90 | CHRNB2 (0.66) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL3357355 | 0.90 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL3361437 | 0.90 | CHRNB2 (0.66) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL3360878 | 0.89 | CHRNB2 (0.63) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445684-B2 | Nicotinic acetylcholine receptor ligands and the uses thereof | PsycoGenics Inc. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445684-B2 | Nicotinic acetylcholine receptor ligands and the uses thereof | PsycoGenics Inc. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445684-B2 | Nicotinic acetylcholine receptor ligands and the uses thereof | PsycoGenics Inc. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010045212-A2 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INCSTATUTS (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | CHRNB2 12/4885CHRNA4 5/4885CHRNA3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.